Laura K. Ferris

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation

Angela Bononi, Carlotta Giorgi, Simone Patergnani et al. · Nature · 2017 · 398 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter et al. · Journal of Allergy and Clinical Immunology · 2015 · 250 citations

Medicine, Immunology, Pharmacology +15

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

Bruce Strober, Craig L. Leonardi, Kim Papp et al. · Journal of the American Academy of Dermatology · 2016 · 130 citations

Pharmacy, Immunology, Pharmacotherapy +17

Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay

Miao He, Lisa E. Kratz, Joshua J. Michel et al. · Journal of Clinical Investigation · 2011 · 113 citations · Full text

Life Sciences, Dermatology, Genetics +17